Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Rosetta Genomics partners with Admera Health for commercialization of oncology tests

Rosetta Genomics (ROSG) has partnered with Admera Health, a spin-off from the clinical services unit of Genewiz.

Focused on personalized medicine, Admera Health is a molecular diagnostics company that aims to develop and deliver cost-effective tests that fulfill unmet medical needs, including clinical molecular oncology diagnostics.

Under the agreement, Rosetta Genomics will leverage its commercial infrastructure and expertise to market and sell Admera Health’s tests to oncologists and pathologists. Rosetta Genomics expects to record initial revenue from these test sales by year end, with more significant revenue expected to be generated beginning in 2015 and beyond.

Examples of current tests and services to be marketed by Rosetta Genomics include:

PGxOne- A pharmacogenomics test that predicts how patients will respond to drug therapy based on their personal genetic makeup. Because differences between individuals can affect drug absorption, metabolism, or activity, one treatment regimen may work well for one patient while causing adverse effects for other patients. PGxOne provides medically actionable and clinically relevant data for chemotherapy patients, allowing physicians to make effective treatment decisions.

EGFR & KRAS Clinical Sequencing — DNA sequencing and mutation analysis of EGFR and KRAS from patient tissue and blood provides clinically relevant genomic information for physicians, pathologists, and researchers. EGFR and KRAS sequence analysis of tumor biopsies predicts tumor response to specific antineoplastic drugs.

Most often used in the treatment of non-small cell lung and colorectal cancers, these assays are predictive and prognostic indicators for patients on tyrosine kinase inhibitor drugs, such as Erlotinib (Tarceva) and Gefitinib (Iressa), and anti-EGFR monoclonal antibodies drugs, such as panitumumab (Vectibix) and cetuximab (Erbitux).

"Through this partnership, we are able to engage Rosetta’s extensive network of physicians and healthcare professionals to offer greater personalized testing options for patients," commented Steve Sun, Chief Executive Officer of Admera Health. "Together, we will provide physicians with the comprehensive information required to implement effective, personalized treatment plans swiftly, bringing the benefit directly to the patient."